Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia. (GENTLE-PACE)
Bradycardia, Syncope
About this trial
This is an interventional treatment trial for Bradycardia focused on measuring cardioneuroablarion, functional bradycardia, pacemaker treatment discontinuation
Eligibility Criteria
Inclusion Criteria: Patients who underwent pacemaker implantation before 50 years old due to sinus node and/or atrioventricular node dysfunction Positive response to atropine test Age between 18-65 years Signed informed consent to participate in the study Exclusion Criteria: Own heart rate <30/min Fainting after pacemaker therapy initiation Persistent and sustained atrial fibrillation History of myocarditis History of cardiac surgery History of ablation procedures Congenital heart defects Congenital atrioventricular block Neuromuscular and neurodegenerative diseases Indications for expanding the pacemaker system to ICD/CRT-D Pregnancy Renal insufficiency with GFR <30 ml/min/1.73m2
Sites / Locations
- Mazowiecki Specialist Hospital
- Medical University of Silesia
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Group 1
Group 2
Group 3
Group 1 will undergo EPS, ECVS, CNA with continuation of PM therapy and ILR implantation. Two months later pacing rate, will be assessed. In addition, there will be a non-invasive assessment of the effectiveness of CNA. After another month, EPS and ECVS will be performed and a re-CNA if the ECVS does not show full parasympathetic denervation of the heart. For patients with ECVS-confirmed successful CNA, the pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, the pacing rate will be assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During the next 4 visits repeated every 3 months, patients in this group will undergo non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, patients in this group will be qualified to discontinue of the cardiac pacing treatment, with possible qualification for TLE.
Group 2 will undergo EPS and ECVS with continuation of PM therapy, ILR implantation, without CNA. Two months later pacing rate, will be assessed. After another month, EPS, ECVS and CNA will be made. For patients with ECVS-confirmed successful CNA, the pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, patients in this group will have their pacing rate assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During next 4 visits repeated every 3 months, patients in this group will undergo a non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, the qualification for discontinuation of cardiac pacing treatment will take place, with possible qualification for TLE.
Group 3 patients will only be observed for the duration of the study. The observation period will be 18 months. At subsequent visits 1, 3, 4, 6, 9, 12, 15 months after randomization, they will be assessed for the presence of MAS, paraMAS and assessment of the percentage of stimulation.